ABOUT THE EVENT
Date: Tuesday, December 2, 2025 8am–5pm EST
Event Location: Munich, Germany
Oligonucleotide Therapeutics Xchange – Europe 2025
Date & Time: Tuesday 2nd December 2025 | 08:00 – 17:45Venue: Hilton Munich Airport Hotel, Terminalstraße Mitte 20, 85356 München-Flughafen, Germany
Welcome to hubXchange’s Oligonucleotide Therapeutics Xchange Europe 2025.
This interactive meeting brings together senior scientists and executives from pharma and biotech to address key challenges in Innovation in Therapeutic Modalities, Translational & Clinical Strategy, Oligonucleotide CMC & Process Development, and Drug Delivery.
Attendees will benefit from expert-led roundtables, pre-booked 1:1 meetings, high-level presentations, poster sessions, and networking, creating a collaborative space to share insights and accelerate oligonucleotide therapeutics.
Agenda Highlights
- New Frontiers in RNA-Targeting Oligonucleotides: Beyond Splicing and Silencing – Marie Wikström Lindholm, CSO, Silence Therapeutics
- Next-Generation Oligonucleotides: Creative Strategies for Molecule Design and Targeted Delivery – Kerstin Hofer, Roche
- Hurdles to Overcome from Preclinical Development into GMP Manufacturing – Tobias Pöhlmann, CEO, XNApharma
- Translating Small RNA Therapeutics into Respiratory Virus Preventives – Simone Carneiro, Ludwig-Maximilians-Universität München
- Breakthroughs in LNP Formulation and Analytics – Nadja Berger, Head of Chemistry, CPTx
- Spotlight and Poster Sessions – Cutting-edge developments in RNA and peptide therapeutics
Why hubXchange?
hubXchange’s format is designed for maximum engagement and collaboration, setting it apart from traditional conferences:
- Focused roundtables on real-world challenges
- Curated 1:1 meetings for strategic networking
- Interactive presentations and posters showcasing breakthrough science
- A community environment where discussions are practical, not forced
“hubXchange offers a much more useful and natural way to connect compared to larger conferences – a mix of open discussion and personal interaction that feels authentic.”— Senior Director, Clinical Development, Biotech
